Novartis has decided it will not be exercising its option for Transgene's targeted cancer immunotherapy TG4010 MUC1 which is in Phase II development for non-small cell lung cancer (NSCLC).
Transgene's shares were trading at €9.44, 14% down compared with the previous day's close, at 1pm GMT (29 April) on the news.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?